Recent developments in the use of organic-inorganic nanohybrids for drug delivery.

Organic-inorganic nanohybrid (OINH) structures providing a versatile platform for drug delivery with improved characteristics are an area which has gained recent attention. Much effort has been taken to develop these structures to provide a viable treatment options for much alarming diseases such as cancer, bone destruction, neurological disorders, and so on. This review focuses on current work carried out in producing different types of hybrid drug carriers identifying their properties, fabrication techniques, and areas where they have been applied. A brief introduction on understating the requirement for blending organic-inorganic components into a nanohybrid drug carrier is followed with an elaboration given about the different types of OINHs developed currently highlighting their properties and applications. Then, different fabrication techniques are discussed given attention to surface functionalization, one-pot synthesis, wrapping, and electrospinning methods. Finally, it is concluded by briefing the challenges that are remaining to be addressed to obtain multipurpose nanohybrid drug carriers with wider applicability. This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies.

The effect of collection substrate on electrospun ciprofloxacin-loaded poly(vinylpyrrolidone) and ethyl cellulose nanofibers as potential wound dressing materials.

In this work, nanofibers based on hydrophilic poly(vinylpyrrolidone) (PVP) and hydrophobic ethyl cellulose (EC) were generated via electrospinning. A model antibiotic, ciprofloxacin (CIF), was also incorporated into the fibers. Fibers were collected on both a foil substrate and a commercial gauze, the latter in the interests of developing a smart fabric. Electron microscopy images revealed that the fibers collected on both foil and fabric were homogeneous and cylindrical. Infrared spectroscopy, X-ray diffraction and differential scanning calorimetry demonstrated that CIF was successfully loaded into the fibers and present in the amorphous physical form. In vitro drug release tests were conducted to simulate drug release from the formulations into a wound site, and as expected the hydrophilic fibers showed much faster release than their hydrophobic analogues. CIF was released through a combined mechanism of polymer erosion and drug diffusion, and the EC nanofibers displayed close to zero-order release over three days. Fibroblast cells are able to grow and proliferate on the fibers. Finally, inhibition zone assays revealed that the growth of both Gram positive and Gram negative bacteria could be effectively inhibited as a result of the presence of CIF in the fibers. There were no marked differences between the fibers collected on foil and on gauze, and electrospinning can be performed directly onto a gauze substrate to prepare a smart fabric.

Tunable drug release from blend poly(vinyl pyrrolidone)-ethyl cellulose nanofibers.

The management of pain and inflammation arising from wounds is essential in obtaining effective healing rates. The application of a wound dressing loaded with an anti-inflammatory drug would enable both issues to be ameliorated, and the aim of this work was to fabricate such a dressing by electrospinning. Fibers comprising ethyl cellulose (EC) and poly(vinyl pyrrolidone) (PVP) loaded with naproxen (Nap) were developed to be used in the early stages of wound care. A family of PVP/EC/Nap systems was prepared by varying the PVP: EC ratio. In all cases, the products of electrospinning comprise non-woven mats of fibers which generally have smooth and cylindrical morphologies. The formulations exist as amorphous solid dispersions, and there appear to be intermolecular interactions between the three components. Adjusting the polymer ratios results in tunable drug release, and formulations have been produced which give zero-order drug release over 20 and 80 h. The fiber mats generated in this work thus have great potential to be used as dressings for the treatment of wound pain and inflammation.